Expect more M&A in 2025, analysts say

Today’s Big News

Jan 3, 2025

Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: Evaluate

Analysts predict M&A, IPO uptick in 2025 but don't expect 'floodgates to suddenly open'

Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio

Study sparks call for funding reforms to protect patient groups from pharma influence

FDA completes first phase of study into potential metal exposure from tampons

 

Featured

Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: Evaluate

By Fraiser Kansteiner

Even as Novo and Lilly continue to climb, Roche looks poised to remain the top drugmaker by revenue in 2025, Evaluate analysts predict.
 

Top Stories

Analysts predict M&A, IPO uptick in 2025 but don't expect 'floodgates to suddenly open'

By Nick Paul Taylor

Will 2025 be better? After another tough year, the answer to that question will shape the prospects of innumerable drug candidates and the lives of people who work in biotech. Evaluate analysts made predictions in their 2025 preview—and anyone expecting a dramatic turnaround should look away now.

Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio

By Gabrielle Masson

Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of 2024.

Study sparks call for funding reforms to protect patient groups from pharma influence

By Nick Paul Taylor

Academics are calling for governments to act to “safeguard the independence” of patient groups that receive funding from biopharma companies. The call reflects a belief “drug companies shape and mold patient organizations over time” through financial support.

FDA completes first phase of study into potential metal exposure from tampons

By Conor Hale

An independent review of scientific literature searched for contaminants in tampons, including not just metals but also phthalates, parabens and volatile organic compounds.

Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatide

By Fraiser Kansteiner

After plugging $23 billion into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to wade into a lawsuit that could allow compounding pharmacies to continue churning out the popular diabetes and obesity drugs.

Chutes & Ladders—Vincerx acquisition leads to C-suite shake-up

By Darren Incorvaia,Zoey Becker

After being acquired by clinical-stage ADC company Oqory, Vincerx ended 2024 with a workforce reduction and C-suite clear-out that will involve Ahmed Hamdy, M.D., stepping down as CEO, while remaining as chairman.

BioNTech inks settlements with NIH, UPenn in COVID-19 vaccine royalty disputes

By Zoey Becker

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million through the royalty settlements on the Pfizer-partnered COVID-19 vaccine Comirnaty.

CRO Veeda unveils ‘modern and dynamic’ rebrand to mirror expansion into CDMO services

By Andrea Park

New year, new Veeda. The India-based CRO formerly known as Veeda Group has kicked off 2025 with a brand makeover.

Drug candidate restores myelin and leg mobility in multiple sclerosis mouse model

By Darren Incorvaia

An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in mice, the biotech announced Dec. 23.
 
Fierce podcasts

Don’t miss an episode

'The Top Line': Fierce 50 honorees look ahead: AI, rural health, antibiotic resistance, maternal care and more

This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees.

'The Top Line': What can we learn from 2024’s biotech IPOs?

'Podnosis’: Integrating social-emotional learning in child education

 

Upcoming Fierce Events

14-15
Jan
Fierce JPM Week
San Francisco, CA
22-24
Jan
Fierce JPM Week - Virtual Event
Virtual Event
29-1
Apr-May
Fierce Pharma Engage
San Diego, CA
7-9
May
Fierce Pharma Marketing Innovation Week
Free Virtual Event
8-11
Sep
Fierce Pharma Week
Philadelphia, PA

View all events